Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice.

Current radiopharmaceuticals

Volumn 6, Issue 2, 2013, Pages 106-116

  Heyerdahl, Helen ^a   Abbas, Nasir ^b   Sponheim, Kristine ^b   Mollatt, Camilla ^b   Bruland, Øyvind ^b   Dahle, Jostein ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT; THORIUM-227DOTA-P-BENZYL-TRASTUZUMAB;

ALPHA RADIATION; ANIMAL; FEMALE; METABOLISM; MOUSE; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; OVARIAN NEOPLASMS; PROCEDURES; RADIOIMMUNOTHERAPY; THERAPEUTIC USE; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84891385840     PISSN: None     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/18744710113069990018     Document Type: Article

References (0)